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Abstract:  
 Introduction: Diabetes has various health impacts including 
inflammatory processes. Aspirin is used as anti-inflammatory treatment.  
Study objectives: to study the prevalence of aspirin use among diabetic 
patients. 
Methods and subjects:  a retrospective study design was employed to 
collect data from study participants who attended internal medicine clinics at 
Rashid Prince Hospital. A total of 447 files of diabetic patients were 
reviewed. Study variables included age, gender, body mass index, aspirin 
intake, cardiac diseases, family history of cardiac diseases, and family 
history of diabetes. Data were analyzed using SPSS version 20. 
Study findings: the mean age of participants was 55.58+ 10.46 years, 47% 
of participants were males, and the mean of BMI was 39.18 which implied 
that participants in general were obese. Aspirin intake was reported by 43% 
of participants, about 76% of participants had cardiac disease, about 63% of 
patients had a family history of cardiac disease, and 31% had a family 
history of diabetes.  Aspirin intake was associated significantly with gender 
(P=0.001) and females were more likely to intake aspirin. No other 
significant association was observed between aspirin intake and other study 
variables.  
Conclusion: the study findings showed that 43% of diabetic patients 
received aspirin as a treatment, while diabetic patients who had cardiac 
problems were 76% which implies that the prescription policy of aspirin 
needs to be revised. 
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Introduction 
 The most common risk factors causing mortality and morbidity 
among diabetics are myocardial infarction and stroke (Moss et al., 1991; 
Koskinen et al., 1998).  Diabetics are 2-4 times more likely to develop CVD 
than non-diabetics (Haffner et al., 1998). 
 Aspirin treatment is characterized by being easy, safe and cheap 
preventive medical consideration as an effective therapeutic for both primary 
and secondary prevention of cardiovascular events and cardiac mortality 
(Hansson et al., 1998; Collaborative Group of the Primary Prevention 
Project, 2001).  
 Rolka, Fagot-Campagna, and Narayan (2001) conducted a study to 
explore the prevalence of using aspirin among diabetics and found that about 
27% of diabetics had cardiovascular disease (CVD), and it was also found 
that 71% of diabetics had at least one risk factor for CVD. The study 
findings showed that the rate of aspirin use was 37% among diabetics who 
had CVD in addition to 13% among those with risk factors. 
 Sarah et al (2002) conducted a study to investigate both physician 
practices and the use of aspirin therapy by diabetics. Study findings indicated 
that 71% of participants were counselled regarding the prescription of 
aspirin, and 66% reported aspirin daily taking. It was interesting to find 
aspiring therapy counselling as the most significant factor associated with 
aspirin use.   
 Fu et al (2005) conducted a study to investigate the prevalence of 
aspirin use among diabetics in Taiwan. Study findings showed that the 
prevalence of aspirin prescription was about 12%, a higher rate of aspirin 
prescription (17%) was observed among diabetics within the age group 70 
years and over. On the other hand, the prescription rate of aspirin was 6%, 
and less observed among diabetics within the age group 50 years or under. 
The results also indicated that patients, who had stroke or coronary heart 
disease, had higher rates of aspirin prescription (49.6% and 49.2% 
respectively).  
 Ghadiri-Anari et al (2013) conducted a study to investigate the 
prevalence of aspirin intake among diabetics and associated CVD risk 
factors. Study findings showed that aspirin was used by 58% of diabetics. As 
a conclusion, diabetics should use more aspirin if its benefits exceed its 
potential harms.   
 Habizal et al (2015) conducted a study to evaluate the prevalence of 
aspirin resistance and its associated factors. Study findings showed that 
about 17% of diabetics had aspirin resistance. Study findings also indicated 
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that markers of Glycaemic control (HbA1c) and inflammatory markers 
(CRP) had no significant association with aspirin resistance.  
 
Methods and subjects:  
 A retrospective study design was employed to collect data from study 
participants who attended internal medicine clinics at Rashid Prince 
Hospital. A total of 447 files of diabetic patients were reviewed. Study 
variables included age, gender, body mass index, aspirin intake, cardiac 
diseases, family history of cardiac diseases, and family history of diabetes. 
Data were analyzed using SPSS version 20. 
 
Study results 
The main characteristics of participants 
 As shown in table 1, the mean age of study participants was 55.58+ 
10.46 years. Males were 47% of participants. The prevalence of aspirin 
prescription was 43%. Cardiac diseases were reported in about 76% of 
diabetics, family history of cardiac diseases was shown in about 63% of 
participants, and family history of diabetes was reported in about 31% of 
cases. 
Table 1: The main characteristics of participants 
Variable Description 
Age (M+SD) years 55.58 + 10.46 
Gender (N, %) 
- Male 
- Female 
 
210 (47) 
237 (53) 
Aspirin prescription (N, %) 
- Yes 
- No 
 
192 (43) 
255 (57) 
Cardiac disease (N, %) 
- Yes 
- No 
 
339 (75.8) 
108 (24.2) 
Family history of cardiac disease (N, %) 
- Yes 
- No 
 
280 (62.6) 
167 (37.4) 
Family history of diabetes (N, %) 
- Yes 
- No 
 
137 (30.6) 
310 (69.4) 
 
The association between aspirin use and study variables 
 We investigated the association of aspirin prescription with other 
study variables. Gender was the only variable to associate significantly with 
aspirin prescription with an obvious female preference (p= 0.001). The other 
variables did not show a significant association with aspirin prescription 
(p>0.05), these variables included cardiac disease, family history of cardiac 
disease, and family history of diabetes (table 2).  
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Table 2: The association between aspirin use and study variables 
Variable Aspirin P value 
Yes No 
N % N % 
Gender 
- Male 
- Female 
 
73 
119 
 
38 
62 
 
137 
118 
 
53.7 
46.3 
 
0.001 
Cardiac disease 
- Yes 
- No 
 
152 
40 
 
79.2 
20.8 
 
187 
68 
 
73.3 
26.7 
 
0.154 
 
Family history of cardiac 
disease 
- Yes 
- No 
 
 
123 
69 
 
 
64.1 
35.9 
 
 
157 
98 
 
 
61.6 
38.4 
 
0.590 
Family history of diabetes 
- Yes 
- No 
 
55 
137 
 
28.6 
71.4 
 
82 
173 
 
32.2 
67.8 
 
0.425 
 
  
Discussion  
 The current study was conducted to explore the prevalence of aspirin 
use and associated risk factors. The prevalence of aspirin prescription was 
43%.  Studies showed variations in the prevalence of aspirin use.  The study 
of Rolka, Fagot-Campagna, and Narayan (2001) reported that the rate of 
aspirin use was 37% among diabetics who had CVD. The prevalence of 
aspirin prescription was 66% in the study of Sarah et al (2002).  In Taiwan, 
Fu et al (2005) reported a 12% prevalence of aspirin use. In Iran,   Ghadiri-
Anari et al (2013) reported that the prevalence of aspirin prescription was 
58% among diabetics. Although aspirin has various benefits, Habizal et al 
(2015) indicated to aspirin resistance by 17% of diabetics.   
 The data of our study indicated that aspirin prescription was 
associated significantly with gender (p=0.001), with a clear preference by 
females. This trend was obvious in other studies such as the study of   Rolka, 
Fagot-Campagna, and Narayan (2001). 
 Our data did not show a significant association between aspirin 
prescription and each of cardiac disease, family history of cardiac disease 
and family history of diabetes (p>0.05). Actually, our findings do not agree 
with other reported studies in which aspirin treatment is shown more among 
diabetics with risk factors such as CVD (Moss et al., 1991; Hansson et al., 
1998; Koskinen et al., 1998; Collaborative Group of the Primary Prevention 
Project, 2001; Sarah et al., 2002). 
 
Conclusion 
 Although the prevalence of aspirin prescription in this study (43%) is 
considered good compared with other studies, more attention should be 
given to prescribe more aspirin for diabetics because of its protective effects.  
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